News
Article
Author(s):
SeqOne's acquisition of Congenica enhances its AI-driven genomic solutions, expanding global reach and transforming genetic data analysis for personalized medicine.
The acquisition sees that SeqOne will provide service to over 160 laboratories spanning across 30 countries.
Stock.adobe.com
SeqOne announced its acquisition of Congenica, creating one of the largest international “software pure players” within the genomic industry, while also expanding SeqOne’s market position to 160 labs across 30 countries worldwide.
“The Board of Congenica is proud of the immense impact our technology has had on healthcare since our inception,” said Dr Andy Richards CBE, chairman of Congenica. “We support this combination with SeqOne, believing their vision and resources are best positioned to carry that legacy forward and ensure our innovative platform continues to thrive and serve patients globally.”1
SeqOne, an AI-powered platform providing clinical decision-support tools enabling molecular laboratories to deliver accelerated, accurate, and scalable analysis of genetic data for applications in oncology, rare and inherited diseases, and infectious diseases.
“The rapid pace of personalized medicine demands continuous investment in software innovation and deep specialization,” said Martin Dubuc, CEO of SeqOne. “By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market––a global leader in clinical genomics since the landmark 100,000 Genomes Project.”1
The acquisition will conjoin SeqOne’s AI-powered platform designed for Next-Generation Sequencing (NGS) analysis with Congenica’s clinical decision support technology, along with its clinical interpretation services.1 The technological integration aims to transform complex genomic data into rapid, actionable insights, while accelerating diagnosis for families of patients suffering from rare disease, while also enabling accurate and individualized cancer therapy options.
The diminishing price of sequencing a human genome created a “data tsunami” and formed a new challenge in interpreting data for hospitals and labs. Referred to as the “interpretation bottleneck,” it stands as the largest hurdle in the way of delivering personalized medicines, with the only solution stemming from high powered and intelligent software.
SeqOne’s acquisition of Congenica comes at a time in which the company is doubling its revenue while also expanding its international presence. SeqOne’s foothold will increase from just three countries to over 30 in less than a 12-month span. This acquisition also follows the company’s successful procurement of Life & Soft, which occurred back in April of this year, and expanded the company’s capabilities into multi-omics and virology.
SeqOne’s funding recently received a boost from its $26.8 million funding round, allowing the company to execute its plans for consolidating a fragmented market and contrasting the definitive software operating system for clinical genomics.
With Congenica’s acquisition, SeqOne now serves over 160 customer laboratories in more than 30 countries, leads a team of over 125 employees, and plans to conduct over 200,000 patient genomic analyses in 2025.
SeqOne also ensured its commitment to continuity of service and support for current Congenica customers, providing access to an expanded and integrated product portfolio, while also maintaining its presence at the Wellcome Sanger Institute.1
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
